Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
- Previous Close
269.00 - Open
269.00 - Bid 266.20 x --
- Ask 266.60 x --
- Day's Range
264.60 - 272.60 - 52 Week Range
189.03 - 302.00 - Volume
590,472 - Avg. Volume
542,190 - Market Cap (intraday)
90.677B - Beta (5Y Monthly) 0.26
- PE Ratio (TTM)
36.05 - EPS (TTM)
7.40 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
333.50
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.
www.sobi.com1,772
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SOBI.ST
Performance Overview: SOBI.ST
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SOBI.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SOBI.ST
Valuation Measures
Market Cap
91.42B
Enterprise Value
111.01B
Trailing P/E
36.40
Forward P/E
27.62
PEG Ratio (5yr expected)
1.73
Price/Sales (ttm)
3.96
Price/Book (mrq)
2.70
Enterprise Value/Revenue
5.02
Enterprise Value/EBITDA
15.34
Financial Highlights
Profitability and Income Statement
Profit Margin
10.89%
Return on Assets (ttm)
4.61%
Return on Equity (ttm)
7.98%
Revenue (ttm)
22.12B
Net Income Avi to Common (ttm)
2.41B
Diluted EPS (ttm)
7.40
Balance Sheet and Cash Flow
Total Cash (mrq)
904M
Total Debt/Equity (mrq)
60.49%
Levered Free Cash Flow (ttm)
-375k
Research Analysis: SOBI.ST
Company Insights: SOBI.ST
SOBI.ST does not have Company Insights